Israeli oncology company Alpha Tau Medical Ltd. (DRTS) drew strong attention after the stock surged to a new 52-week high of $5.07 on December 10. It closed at $5.06, marking a 19.62% gain for the day, and extended its rise to $5.20 in after-hours trading. The strong price action comes at a time when the company is advancing several clinical programs, expanding its manufacturing capabilities, and preparing for multiple regulatory and clinical milestones across 2025 and 2026. These developments have placed the stock firmly on the radar as Alpha Tau continues to progress its Alpha DaRT radiation therapy platform.
What the Company Does
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com